Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability
Authors:
- 2 June 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (10) , 1511-1521
Abstract
Introduction: Walking impairment is a clinical hallmark of multiple sclerosis (MS), a chronic neurologic disease characterized by axonal demyelination and dysfunction that results in progressive disability. Until recently, there were no therapies that specifically targeted the axonal dysfunction associated with walking impairment in MS. Areas covered: The purpose of this review is to discuss the unmet need for the treatment of walking impairment in MS patients and to evaluate how a new class of pharmacologic therapies, neurofunctional modifiers, potentially addresses this unmet need. Discussion is based on clinical experience and opinions supported by publications identified in the PubMed literature using the search terms ‘multiple sclerosis’ and ‘mobility OR walking’. Expert opinion: The development and approval of new treatments for MS show promise for improving adherence to therapy and increasing the potential for clinical effectiveness. Renewed emphasis on integrating strategies that target the underl...Keywords
This publication has 83 references indexed in Scilit:
- Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: A phase I–II, open-label trialClinical Therapeutics, 2009
- Employment in multiple sclerosisJournal of Neurology, 2008
- Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis StudyMultiple Sclerosis Journal, 2008
- Symptoms and physical activity behavior in individuals with multiple sclerosisResearch in Nursing & Health, 2008
- The burden of multiple sclerosis: A community health surveyHealth and Quality of Life Outcomes, 2008
- Costs and quality of life of patients with multiple sclerosis in EuropeJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Secondary progressive multiple sclerosis: current knowledge and future challengesThe Lancet Neurology, 2006
- Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosisActa Neurologica Scandinavica, 2002
- Atypical Presentation of 4-Aminopyridine OverdoseAnnals of Emergency Medicine, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983